Price
$0.73
Decreased by -1.50%
Dollar Volume
183.87 K
ADR%
12.63
Earnings Report Date (estimate)
Mar 6, 23 (-0.19)
Market Cap.
72.34 M
Shares Float
70.79 M
Shares Outstanding
99.10 M
Beta
1.10
Price / Earnings
-0.69
BPR
8.42
20D Range
0.52 0.80
50D Range
0.46 1.45
200D Range
0.46 3.74
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 14, 22 -0.18
Decreased by -20.00%
-0.19
Increased by +5.26%
Aug 15, 22 -0.23
Increased by +36.11%
-0.28
Increased by +17.86%
May 16, 22 -0.21
Increased by +48.78%
-0.30
Increased by +30.00%
Mar 8, 22 -0.35
Decreased by -6.06%
-0.25
Decreased by -40.00%
Nov 9, 21 -0.15
Increased by +54.55%
-0.33
Increased by +54.55%
Aug 5, 21 -0.36
Decreased by -2.86%
-0.33
Decreased by -9.09%
May 6, 21 -0.41
Decreased by -5.13%
-0.33
Decreased by -24.24%
Feb 23, 21 -0.33
Increased by +15.38%
-0.32
Decreased by -3.13%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 2.96 M
Decreased by -5.19%
-15.71 M
Decreased by -74.77%
Decreased by -530.57%
Decreased by -84.34%
Jun 30, 22 3.86 M
Increased by +37.99%
-17.80 M
Increased by +17.86%
Decreased by -461.10%
Increased by +40.47%
Mar 31, 22 2.96 M
Increased by +17.47%
-14.19 M
Increased by +41.48%
Decreased by -479.55%
Increased by +50.18%
Dec 31, 21 3.34 M
Increased by +7.53%
-22.80 M
Decreased by -20.57%
Decreased by -682.11%
Decreased by -12.13%
Sep 30, 21 3.12 M
Decreased by -12.99%
-8.99 M
Increased by +52.09%
Decreased by -287.83%
Increased by +44.94%
Jun 30, 21 2.80 M
Increased by +31.67%
-21.67 M
Decreased by -12.71%
Decreased by -774.62%
Increased by +14.40%
Mar 31, 21 2.52 M
Increased by +7.51%
-24.24 M
Decreased by -13.75%
Decreased by -962.63%
Decreased by -5.80%
Dec 31, 20 3.11 M
Decreased by -10.40%
-18.91 M
Increased by +11.36%
Decreased by -608.30%
Increased by +1.06%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.